Ianalumab

The global lupus nephritis market is projected to grow significantly by 2034, with the United States accounting for over 80% of the current $1.12 billion market share across major regions.

The FDA has granted orphan drug designation to Novartis' Ianalumab for the treatment of primary immune thrombocytopenia, highlighting potential new treatment options for this rare blood disorder.

The lupus nephritis clinical trial pipeline is robust, featuring over 30 companies developing more than 35 therapies.

Scemblix (asciminib) demonstrates favorable safety and tolerability compared to investigator-selected TKIs in newly diagnosed CML-CP patients.

Scemblix (asciminib) demonstrates favorable safety and tolerability in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) patients after 96 weeks, based on the Phase 3 ASC4FIRST study.